» Articles » PMID: 29475983

S1P-S1PR2 Axis Mediates Homing of Muse Cells Into Damaged Heart for Long-Lasting Tissue Repair and Functional Recovery After Acute Myocardial Infarction

Abstract

Rationale: Multilineage-differentiating stress enduring (Muse) cells, pluripotent marker stage-specific embryonic antigen-3 cells, are nontumorigenic endogenous pluripotent-like stem cells obtainable from various tissues including the bone marrow. Their therapeutic efficiency has not been validated in acute myocardial infarction.

Objective: The main objective of this study is to clarify the efficiency of intravenously infused rabbit autograft, allograft, and xenograft (human) bone marrow-Muse cells in a rabbit acute myocardial infarction model and their mechanisms of tissue repair.

Methods And Results: In vivo dynamics of Nano-lantern-labeled Muse cells showed preferential homing of the cells to the postinfarct heart at 3 days and 2 weeks, with ≈14.5% of injected GFP (green fluorescent protein)-Muse cells estimated to be engrafted into the heart at 3 days. The migration and homing of the Muse cells was confirmed pharmacologically (S1PR2 [sphingosine monophosphate receptor 2]-specific antagonist JTE-013 coinjection) and genetically (S1PR2-siRNA [small interfering ribonucleic acid]-introduced Muse cells) to be mediated through the S1P (sphingosine monophosphate)-S1PR2 axis. They spontaneously differentiated into cells positive for cardiac markers, such as cardiac troponin-I, sarcomeric α-actinin, and connexin-43, and vascular markers. GCaMP3 (GFP-based Ca calmodulin probe)-labeled Muse cells that engrafted into the ischemic region exhibited increased GCaMP3 fluorescence during systole and decreased fluorescence during diastole. Infarct size was reduced by ≈52%, and the ejection fraction was increased by ≈38% compared with vehicle injection at 2 months, ≈2.5 and ≈2.1 times higher, respectively, than that induced by mesenchymal stem cells. These effects were partially attenuated by the administration of -gene-silenced Muse cells. Muse cell allografts and xenografts efficiently engrafted and recovered functions, and allografts remained in the tissue and sustained functional recovery for up to 6 months without immunosuppression.

Conclusions: Muse cells may provide reparative effects and robust functional recovery and may, thus, provide a novel strategy for the treatment of acute myocardial infarction.

Citing Articles

Effects of Muse Cell on a Mouse Model With Acute Encephalopathy.

Kawaguchi T, Mori T, Adachi K, Fujii J, Maegaki Y, Obata F Brain Behav. 2025; 15(1):e70242.

PMID: 39829154 PMC: 11743977. DOI: 10.1002/brb3.70242.


Restoration effect of chemically modified microRNA-143-3p on acute myocardial infarction in animal models.

Minatoguchi S, Sugito N, Heishima K, Ito Y, Nakashima R, Okura H Sci Rep. 2025; 15(1):1107.

PMID: 39774185 PMC: 11707079. DOI: 10.1038/s41598-024-76429-3.


Accumulation of endogenous Muse cells in the myocardium and its pathophysiological role in patients with fulminant myocarditis.

Toyoda S, Sakuma M, Ishida K, Kushida Y, Soma R, Takayama H Clin Transl Sci. 2024; 17(11):e70067.

PMID: 39543854 PMC: 11564339. DOI: 10.1111/cts.70067.


Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial).

Sato Y, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R Stem Cells Transl Med. 2024; 13(11):1053-1066.

PMID: 39401019 PMC: 11555474. DOI: 10.1093/stcltm/szae071.


Intravenous administration of muse cells improves cerebral ischemia outcome via immunomodulation in the spleen.

Kato Y, Aburakawa D, Tashiro R, Zhou Y, Rashad S, Endo H J Cereb Blood Flow Metab. 2024; 45(3):542-557.

PMID: 39397400 PMC: 11563515. DOI: 10.1177/0271678X241290363.